Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other research analysts have also weighed in on the company. Citigroup increased their price target on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Leerink Partners lifted their price objective on Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, December 26th. The Goldman Sachs Group dropped their target price on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research note on Thursday, November 20th. Bank of America raised their price target on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Finally, HC Wainwright lifted their price target on Agios Pharmaceuticals from $62.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $40.67.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $27.85 on Friday. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -3.92 and a beta of 0.89. The stock has a fifty day moving average of $28.14 and a two-hundred day moving average of $32.90.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,872 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $27.02, for a total value of $77,601.44. Following the transaction, the insider directly owned 34,793 shares in the company, valued at $940,106.86. This trade represents a 7.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Cecilia Jones sold 2,932 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the completion of the transaction, the chief financial officer directly owned 37,394 shares in the company, valued at $1,013,003.46. This represents a 7.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,262 shares of company stock valued at $984,237 over the last three months. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors have recently bought and sold shares of AGIO. T. Rowe Price Investment Management Inc. purchased a new stake in Agios Pharmaceuticals during the 4th quarter worth $25,000. First Horizon Corp purchased a new position in Agios Pharmaceuticals in the third quarter valued at about $45,000. Assetmark Inc. raised its position in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 362 shares during the period. NewEdge Advisors LLC acquired a new position in shares of Agios Pharmaceuticals during the first quarter worth about $40,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth about $49,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.